» Articles » PMID: 33380212

Association Between the Anticancer Efficacy of Cabazitaxel and Toll-like Receptor 4 Mediating Signaling Pathways in Metastatic Castration-resistant Prostate Cancer Cells

Overview
Journal Hum Exp Toxicol
Publisher Sage Publications
Specialty Toxicology
Date 2020 Dec 31
PMID 33380212
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We evaluated the effect of cabazitaxel (CAB) as a third-line taxane on Toll-like receptor 4 (TLR4)-mediated signaling pathways, especially NF-κB activity, in metastatic castration-resistant prostate cancer (mCRPC) cells.

Methods: CAB cytotoxicity was determined by WST-1 assay. To assess the relationship between CAB efficacy and TLR4 signaling pathways, RT-PCR, western blot and immunofluorescence analysis were performed. Additionally, CAB-mediated apoptotic cell death was assessed by Annexin V and RT-PCR analysis.

Results: Our results demonstrated that CAB exerted considerably cytotoxic and apoptotic effects on PC-3 mCRPC cells (p < 0.05). CAB treatment altered TLR4 expression level in a dose-dependent manner. Furthermore, 1 nM CAB treatment significantly induced NF-κB activity through p65 nuclear localization and increased the expression level of caspase-3, Bax and p53. Interestingly, total apoptotic cell death and IRF3 protein levels were increased at 5 nM concentration of CAB despite a decrease in the levels of both NF-κB and pro-apoptotic genes.

Conclusions: Therefore, NF-κB activity may be a potential target for the efficacy of CAB in mCRPC cells.

Citing Articles

Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes.

Eryilmaz I, Egeli U, Cecener G Cancer Biol Ther. 2024; 25(1):2329368.

PMID: 38485703 PMC: 10950270. DOI: 10.1080/15384047.2024.2329368.


STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.

Rocha S, Nascimento D, Coelho R, Cardoso A, Passarinha L, Socorro S Int J Mol Sci. 2023; 24(7).

PMID: 37047621 PMC: 10095014. DOI: 10.3390/ijms24076643.


Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.

Deveci Ozkan A, Eskiler G, Kaleli S, Sahin E Mol Biol Rep. 2021; 49(2):1261-1271.

PMID: 34826050 DOI: 10.1007/s11033-021-06953-2.